Event Details Catalyst Biosciences at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders February 08, 2019 Supporting Materials Phase 2/3 trial of subcutaneous engineered FVIIa marzeptacog alfa (activated) in hemophilia A or B with inhibitors: Pharmacokinetics, pharmacodynamics, efficacy and safety 6.8 MB Quality of Life For Haemophilia Patients with Inhibitors 591.7 KB AAV Based Hemophilia B Gene Therapy in Mice Using FIX-CB2679d-GT 462.7 KB Shareholder Tools Print Page RSS Feeds E-mail Alerts
Phase 2/3 trial of subcutaneous engineered FVIIa marzeptacog alfa (activated) in hemophilia A or B with inhibitors: Pharmacokinetics, pharmacodynamics, efficacy and safety 6.8 MB
Catalyst Biosciences at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders
